Illumina Radiopharmaceuticals

Innervate Radiopharmaceuticals (formerly Illumina Radiopharmaceuticals) is a clinical-stage biotechnology company specializing in the development of positron emission tomography (PET) imaging agents and therapeutic radiopharmaceuticals. The company's lead program, 18F-mFBG (18F-florbenguane), is a radiolabeled analog of norepinephrine designed to target the norepinephrine transporter (NET) for high-resolution imaging of neuroblastoma and other neural crest tumors. Currently in Phase 3 clinical trials for neuroblastoma, 18F-mFBG aims to provide superior sensitivity and same-day imaging compared to the current standard-of-care MIBG scans. The company is also exploring the tracer's utility in imaging myocardial sympathetic innervation for conditions such as heart failure and Lewy body diseases. Headquartered in Englewood, New Jersey, Innervate is advancing its pipeline through collaborations with leading institutions like Memorial Sloan Kettering Cancer Center.